ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 331 • 2016 ACR/ARHP Annual Meeting

    Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

    Takefumi Furuya1, Eisuke Inoue1,2, Masanori Nakayama1, Eiichi Tanaka1, Katsunori Ikari1, Ayako Nakajima3, Atsuo Taniguchi1 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan, 3Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose:   Previous U.S. and Canadian studies [1-3] have suggested that no significant associations exist between use of biologic disease-modifying anti-rheumatic drugs (DMARDs) and risk of…
  • Abstract Number: 332 • 2016 ACR/ARHP Annual Meeting

    A Comparison of Electronic and Manual Fracture Risk Assessment Tools in Screening US Veterans at Risk for Osteoporosis

    Tyler Williams1, Phillip Lawrence2, Jacob Crook3, Richard Nelson3, Joanne Lafleur4 and Grant W. Cannon5, 1Salt Lake City VA Medical Center and University of Utah Department of Internal Medicine, Salt Lake City, UT, 2Salt Lake City VA Medical Center and Roseman University of Health Sciences, Salt Lake City, UT, 3University of Utah Division of Epidemiology and Salt Lake City VA Medical Center, Salt Lake City, UT, 4University of Utah Department of Pharmacotherapy and Salt Lake City VA Medical Center, Salt Lake City, UT, 5Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT

    Background/Purpose: Osteoporosis-related fractures contribute to increased morbidity and mortality in those affected and substantial economic burden to society. Effective screening for osteoporosis with fracture risk…
  • Abstract Number: 333 • 2016 ACR/ARHP Annual Meeting

    An Assessment of  Bone Health and Fracture Risk in a Bariatric Surgery Population at an Urban Medical Center

    Sherilyn Diomampo1, Leila Muhieddine2, Ann Igoe3, Charles Thomas4 and Sobia Hassan1, 1Rheumatology, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, 2Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, 3Medicine-Pediatrics, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, 4Research, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH

    Background/Purpose:  Bariatric surgery is the most effective treatment for severe obesity.1,2 have been limited and conflicting reports as to the prevalence of osteoporosis and occurrence…
  • Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting

    Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study

    Sarah Dyball1 and Marwan Bukhari2, 1University Hospital South Manchester, Manchester, United Kingdom, 2Royal Lancaster Infirmary, Lancaster, United Kingdom

    Background/Purpose:   Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
  • Abstract Number: 335 • 2016 ACR/ARHP Annual Meeting

    High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis

    Hiranda Dodanwala1, Danielle Feger1, Nicholas Longson2, Nancy J. Olsen3, Barbara E. Ostrov4,5 and Rayford R. June6, 1Medicine - Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, 2Johns Hopkins University, Baltimore, MD, 3Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, 4Pediatrics, Penn State Hershey Medical Center, Hershey, PA, 5Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, 6Rheumatology, Penn State Hershey Medical Center, Hershey, PA

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritides. JIA is the most common cause of musculoskeletal disability in children, and…
  • Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting

    The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab

    DL Kendler1, A Chines2, ML Brandi3, S Papapoulos4, EM Lewiecki5, J-Y Reginster6, C Roux7, M Munoz Torres8, A Wang2 and HG Bone9, 1University of British Columbia, Vancouver, BC, Canada, 2Amgen Inc., Thousand Oaks, CA, 3University of Florence, Florence, Italy, 4Leiden University Medical Center, Leiden, Netherlands, 5New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 6University of Liège, Liège, Belgium, 7Paris Descartes University, Paris, France, 8Hospital Universitario San Cecilio, Granada, Spain, 9Michigan Bone and Mineral Clinic, Detroit, MI

    Background/Purpose:  Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture.  Although osteoporosis therapy decreases fracture risk, fractures while on…
  • Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting

    Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability

    E Siris1, N Pannacciulli2, PD Miller3, EM Lewiecki4, R Chapurlat5, E Jódar-Gimeno6, NS Daizadeh2, RB Wagman2 and JA Kanis7, 1Columbia University Medical Center, New York, NY, 2Amgen Inc., Thousand Oaks, CA, 3Colorado Center for Bone Research, Lakewood, CO, 4New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 5Hôpital Edouard Herriot, Lyon, France, 6Hospital Universitario Quirónsalud Madrid, Madrid, Spain, 7University of Sheffield, Sheffield, United Kingdom

    Background/Purpose:  Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture.  The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…
  • Abstract Number: 338 • 2016 ACR/ARHP Annual Meeting

    Abaloparatide-SC Significantly Reduces Vertebral and Nonvertebral Fractures and Increases Bone Mineral Density (BMD) Regardless of Age, BMD T-Score, or Prior Fracture at Baseline

    F Cosman1, Gary Hattersley2, PD Miller3, Ming-Yu Hu4, Luis Augusto Tavares Russo5, Bente Riis6, Greg Williams7 and Lorraine Fitzpatrick8, 1Clinical Research Center, Helen Hayes Hospital, West Haverstraw, NY, 2Research, Radius Health, Inc., Waltham, MA, 3Colorado Center for Bone Research, Lakewood, CO, 4Biometrics, Radius Health, Inc., Waltham, MA, 5CCBR Brasil, Rua Mena Barreto, 33 Botofogo, 22271, Rio de Janeiro, Brazil, 6Nordic Biosciences A/S, 2730 Herlev, Denmark, 7Clinical Development, Radius Health, Inc., Waltham, MA, 8Chief Medical Officer, Radius Health, Inc., Waltham, MA

    Background/Purpose:  Abaloparatide is a novel 34 amino acid peptide created to be a potent and selective activator of the PTH 1 receptor signaling pathway and…
  • Abstract Number: 339 • 2016 ACR/ARHP Annual Meeting

    Assessment of High-Resolution Peripheral Quantitative Computed Tomography Parameters and Markers of Bone Metabolism in Community-Dwelling Elderly with and without Vertebral Fractures – the Sao Paulo Ageing & Health Study

    Geórgea H. F. Torres1, Luis F S Guzman2, Jaqueline C. Alvarenga3, Levi H J Neto3, Valéria F. Caparbo3, Diogo S Domiciano3, Ricardo M. Oliveira4, Neusa H M Lopes2 and Rosa M R Pereira5, 1Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Cardiologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4RDO Diagnósticos Médicos, São Paulo, Brazil, 5Rheumatology Division, Faculdade de Medicina da USP, São Paulo, Brazil

    Background/Purpose:  Bone mineral density(BMD) by dual X-ray absorptiometry(DXA) is currently standard clinical tool for predicting osteoporotic fracture. However, DXA doesn’t allow studying abnormalities that predict different…
  • Abstract Number: 340 • 2016 ACR/ARHP Annual Meeting

    Hydroxychloroquine: A Potential Treatment for Osteoporosis By Osteoclast Inhibition!

    Tim Both1, Paul L. van Daele2 and Bram Van der Eerden1, 1Internal Medicine, Erasmus MC, Rotterdam, Netherlands, 2Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: We recently showed that patients with primary Sjögren Syndrome (pSS) have significantly higher bone mineral density (BMD) in the lumbar spine and femoral neck…
  • Abstract Number: 341 • 2016 ACR/ARHP Annual Meeting

    Evaluation of 25-Hydroxyvitamin D Levels in Rheumatologic Diseases

    María Lorena Brance1, Lucas Ricardo Brun1, Maria Silvia Larroude2, Mónica Patricia Sacnun3, Carolina Aeschlimann3, Guillermo Berbotto4, Ignacio Chavero1, Mariano Palatnik1 and Ariel Sánchez5, 1Centro de Reumatología., Rosario, Argentina, 2Hospital Milstein, Buenos Aires, Argentina, 3Hospital Provincial, Rosario, Argentina, 4Sanatorio Británico, Rosario, Argentina, 5Centro de Endrocrinología., Rosario, Argentina

    Background/Purpose:  Previous evidence indicates an association between vitamin D deficiency and autoimmune diseases. The aim of this study was to evaluate serum 25 hydroxyvitamin D…
  • Abstract Number: 342 • 2016 ACR/ARHP Annual Meeting

    Presence of Vertebral Fractures and Disc Disease in Post Menopausal Females with Height Loss As a Possible Screening Method for Osteoporosis

    Nicola Berman1, Gregory Chang2 and Stephen Honig1, 1Rheumatology, New York University Department of Rheumatology, New York, NY, 2Radiology, New York University Department of Radiology, New York, NY

    Background/Purpose: The presence of non-traumatic vertebral fracture can identify a patient who has clinical osteoporosis. However, approximately 75% of vertebral fractures are asymptomatic and as many…
  • Abstract Number: 343 • 2016 ACR/ARHP Annual Meeting

    Correlation Between Metacarpal Cortical Bone Mineral Density Measured By Dual X-Ray Densitometry and Radiogrammetry on Early Arthritis Patients

    Irene Llorente Cubas*1, Leticia Merino-Meléndez2, Ana M. Ortiz Garcia3, Saturnino González Ortega4, Eugenio Escolano5, Alberto Garcia-Vadillo6, Esther Vicente-Rabaneda2, Rosario Garcia-Vicuña6, Isidoro Gonzalez-Alvaro3 and Santos Castañeda7, 1Rheumatology, H.U La Princesa, Madrid, Spain, 2Rheumatology, H.U. La Princesa, Madrid, Spain, 3Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 4X-ray diagnosis, X-ray diagnosis, Hospital de La Princesa, Madrid, Spain, 5Radiology Department, H.U La Princesa, Madrid, Spain, 6Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 7Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain

    Background/Purpose: Low bone mass at metacarpal (MC) diaphysis measured by radiogrammetry (DXR) has been described as a poor prognostic factor in rheumatoid arthritis (RA). However,…
  • Abstract Number: 344 • 2016 ACR/ARHP Annual Meeting

    Is Rheumatoid Arthritis a Risk Factor for Fractures: A Systematic Review of Observational Studies

    Ambika Gupta1, Stephanie Pipe2, Tanveer Towheed3 and Tassos Anastassiades2, 1Internal Medicine, Queen's University, Kingston, ON, Canada, 2Queen's University, Kingston, ON, Canada, 3Dept of Medicine, Queen's University, Kingston, ON, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) is a known risk factor for osteoporosis. There are many factors that contribute to this increased risk, including the use of…
  • Abstract Number: 345 • 2016 ACR/ARHP Annual Meeting

    The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)

    Tien-Tsai Cheng1,2, Yin-Chou Chen1,2, Shan-Fu Yu1,2, Han-Ming Lai1,2, Ben Yu-Jih Su1,2, Fu-Mei Su2,3, Wen-Chan Chiu1,2, Chung-Yuan Hsu1,4, Jia-Feng Chen1 and Chi-Hua Ko1, 1Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, 2Chang Gung University College of Medicine, Kaohsiung, Taiwan, 3Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, 4Division of Rheumatology, Allergy, and Immunology, Chang Gung University College of Medicine, Kaohsiung, Taiwan

    Background/Purpose: To explore the relationship of anti-CCP levels with BMD or fragility fracture in patients with RA Methods: This is a prospective cross sectional study.…
  • « Previous Page
  • 1
  • …
  • 1438
  • 1439
  • 1440
  • 1441
  • 1442
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology